Enabling the next generation of therapeutics.
Who we are.
Recognized as the 2022 Top Emerging Company by BIO International, SiVEC Biotechnologies has developed BactPac™, a live biotherapeutic delivery platform to enable the next generation of nucleic acid and gene editing therapies. The collaborative spirit and diversity in scientific expertise of our team supports the rigorous science which is at the core of our company.
SiVEC’s mission is to use our BactPac™ drug delivery platform to develop advanced biologics and out-license the platform to pharma companies who need a safe, tissue-targeted method of delivery to advance nucleic acid and gene therapies into clinical stages.
SiVEC Biotechnologies is quickly gaining traction, including winning the 2022 Women in BIO Innovation Showcase and the 2022 BIO International Start Up Stadium. To date, we have acquired nearly $4 million in non-dilutive funding (National Institutes of Health and State of Colorado).